New Therapies in Veterinary Oncology
- PMID: 38184436
- DOI: 10.1016/j.cvsm.2023.12.003
New Therapies in Veterinary Oncology
Abstract
The expanding number of specialized oncology therapeutics available in veterinary oncology can make staying updated on the most recent advances challenging. This article summarizes the mechanism of action, available supporting data, and clinical use of three key veterinary cancer/supportive care therapeutics: Laverdia-CA1, Canalevia-CA1, and Stelfonta. This information will help guide clinical use within your practice and can be incorporated into discussions with clients regarding the newest available options for their dogs with cancer.
Keywords: Canalevia; Laverdia; Novel therapy; Stelfonta.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure C. Mullin: No disclosures to report. C.A. Clifford: Speaker, advisory board member and consultant with Jaguar Animal Health and Anivive. C.M. Johannes: Speaker, advisory board member and consultant with QBiotics Group; advisory board member with Jaguar Animal Health.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
